Corrections:

Tsion Zewdu Minas^1,*, Jenny Han^1,*, Tahereh Javaheri³, Sung-Hyeok Hong¹, Michaela Schlederer^3,4, Yasemin Saygideğer-Kont¹, Haydar Çelik¹, Kristina M. Mueller⁸, Idil Temel¹, Metin Özdemirli², Heinrich Kovar^7,9, Hayriye Verda Erkizan¹, Jeffrey Toretsky¹, Lukas Kenner^3,4,5, Richard Moriggl^3,6,8 and Aykut Üren¹

¹Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
²Department of Pathology, Georgetown University Medical Center, Washington, DC, USA
³Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
⁴Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
⁵Unit of Pathology of Laboratory Animals, University of Veterinary Medicine, Vienna, Austria
⁶Medical University of Vienna, Vienna, Austria
⁷Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria
⁸Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria
⁹Department of Pediatrics, Medical University of Vienna, Vienna, Austria
^*These authors have contributed equally to this work

Published: February 22, 2024

Copyright: © 2024 Minas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 9, the low magnification liver image from E/F; Mx1-cre, treated with DMSO group (middle row) and the high magnification spleen image from the same group are accidental identical images. The low magnification liver image is correct. The corrected Figure 9, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:37678–37694. DOI: https://doi.org/10.18632/oncotarget.5520

Figure 9: Decreased proliferation was observed in spleens and livers of YK-4-279 treated leukemic mice. E/F; Mx1-cre mice after two weeks treatment with vehicle (middle row) or YK-4-279 (bottom row) were euthanized and spleen and liver samples were processed for histo-pathology analysis. E/F; control mice that lack cre required for EWS-FLI1 activation served as healthy controls (top row) which did not display any symptoms of disease or any peculiar apoptosis or proliferation. Ki67 was used as a marker of proliferation. Ki67 staining of spleen and liver tissues of leukemic E/F;Mx1-cre mice treated with YK-4-279 show a decreased proliferation compared to vehicle treated mice.